IWI ‘ARAD’ and ‘CARMEL’ Rifles to be Manufactured in India’s Madhya Pradesh by PLR

The Israel Weapon Industries (IWI- Formerly owned by the Israel Government, was privatized in 2005 ) Assault Riffle’s- Arad and Carmel will be manufactured at the PLR Systems Private Ltd (PLR- Precise Lethal Reliable) in Madhya Pradesh’s Bhind district. This will be a major boost to the domestic small arms industry and as well as the Make in India initiative.

Both IWI Carmel Assault Rifle and Arad Assault Rifle was a caliber 5.56 X 45 mm, Carmel Assault Rifle has a Rate of Fire (RPM) in between 700-1000 rounds per min.

 PLR Systems Private Limited (PLR)

PLR is an Indian Joint Venture Company with the Israel Weapon Industries (IWI) and is also the First Private Sector Small Arms Manufacturing Plant to be established in India. The PLR manufacturing facility is located at Malanpur Industrial Area of Bhind district. The facility was inaugurated on 4th May 2017. To date for the Indian Armed Forces, PLR has manufactured Small Arms and Ammunition such as TAVOR Assault Rifle, X95 Assualt Riffle, NEGEV Light Machine Gun (World’s Lightest Assault Machine Gun), GALIL Sniper Rifle and UZI Sub Machine Gun.

Russia’s Gamalei Institute’s COVID-19 Vaccine becomes the First in the World to Complete Human Clinical Trials

The COVID-19 vaccine developed by Russia’s Gamalei Institute of Epidemiology and Microbiology has successfully completed the Human Clinical Trials. The trials on volunteers were conducted from 18th June 2020 at Sechenov First Moscow State Medical University.

At Sechenov University, the Director of Institute for Translational Medicine and Biotechnology has informed that the First Group of Volunteers will be released on 15th July 2020 while the Second Group of Volunteers will be released next Monday (20th July 2020).

Outcomes from the Human Clinical Trials

Sechenov University’s Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases have informed that the main objective of the Human Clinical Trials was to study the outcomes for the safety of human health after the vaccine is administered, this has been successfully done during the trials.

The Director has further added that based on outcomes from the human clinical trials such as the complexity of the epidemiological situation with the virus, the decision on scaling up the production of the vaccine will be taken by the Developer – Gamalei Institute of Epidemiology and Microbiology.